Skip to main content
NCBI home page
Annals of Surgery logoLink to Annals of Surgery
. 1992 Jun;215(6):606–617. doi: 10.1097/00000658-199206000-00007

Benefits of quadruple immunosuppressive therapy in recipients of living related donor kidneys. A review of 855 operations.

A G Diethelm 1, D A Laskow 1, S L Hudson 1, M H Deierhoi 1, W H Barber 1, B O Barger 1, B A Julian 1, R S Gaston 1, J J Curtis 1
PMCID: PMC1242513  PMID: 1632682

Abstract

Eight hundred fifty-five living related donor transplant recipients were analyzed according to 15 potential risk factors with regard to patient and graft survival according to immunosuppression. Group I, 1968 to 1983, (n = 440 patients) received azathioprine and prednisone; group II, 1984 to 1987, (n = 229 patients) received triple therapy--azathioprine, prednisone, and cyclosporine; and group III, 1988-1991, (n = 186 patients), quadruple therapy--azathioprine, prednisone, cyclosporine, and Minnesota antilymphocyte globulin. Three important risk factors included immunosuppression, tissue typing, and race. Groups II and III had improved allograft survival over group I (p = 0.03). Patients with two haplotype matches had similar survival in all three groups. Kidney survival in one-haplotype-matched recipients improved in group II and was equal to that of the two-haplotype-matched patients in group III. Cyclosporine improved allograft survival in both races when combined with azathioprine and prednisone. Quadruple therapy improved early survival in one-haplotype black patients, even though long-term results remained better in whites. Cyclosporine did not improve graft survival in two-haplotype recipients. The addition of cyclosporine and quadruple therapy did not increase morbidity and mortality rates.

Full text

PDF
606

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albrechtsen D., Flatmark A., Brynger H., Frødin L., Groth C. G., Persson N. Dual vs triple immunosuppressive therapy: equally safe and effective in kidney transplantation? Transplant Proc. 1991 Aug;23(4):2206–2206. [PubMed] [Google Scholar]
  2. Albrechtsen D., Soedal G., Berg K. J., Bondevik H., Brekke I. B., Fauchald P., Jakobsen A., Opedal B. R., Rugstad H. E., Thorsby E. Cyclosporine in living related and cadaveric renal transplantation. Transplant Proc. 1984 Oct;16(5):1191–1194. [PubMed] [Google Scholar]
  3. Delmonico F. L., Fuller T. C., Cosimi A. B. 1,000 renal transplants at the Massachusetts General Hospital: improved allograft survival for high-risk patients without regard to HLA matching. Clin Transpl. 1990:247–253. [PubMed] [Google Scholar]
  4. Diethelm A. G., Blackstone E. H., Naftel D. C., Hudson S. L., Barber W. H., Deierhoi M. H., Barger B. O., Curtis J. J., Luke R. G. Important risk factors of allograft survival in cadaveric renal transplantation. A study of 426 patients. Ann Surg. 1988 May;207(5):538–548. doi: 10.1097/00000658-198805000-00008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Ferguson R. M., Henry M. L., Sommer B. G., Sachs L., Orosz C. G. A single center experience with cyclosporine in renal transplantation: Ohio State University 1983 to 1987. Clin Transpl. 1987:195–207. [PubMed] [Google Scholar]
  6. Flechner S. M., Kerman R. H., Van Buren C. T., Epps L., Kahan B. D. The use of cyclosporine in living-related renal transplantation. Donor-specific hyporesponsiveness and steroid withdrawal. Transplantation. 1984 Dec;38(6):685–691. doi: 10.1097/00007890-198412000-00027. [DOI] [PubMed] [Google Scholar]
  7. Hesse U. J., Fryd D. S., Chatterjee S. N., Simmons R. L., Sutherland D. E., Najarian J. S. Pulmonary infections. The Minnesota randomized prospective trial of cyclosporine vs azathioprine-antilymphocyte globulin for immunosuppression in renal allograft recipients. Arch Surg. 1986 Sep;121(9):1056–1060. doi: 10.1001/archsurg.1986.01400090086015. [DOI] [PubMed] [Google Scholar]
  8. Hodge E., Banowsky L., Novick A., Lewis R., Streem S., Steinmuller D., Holzmann J., McFarlin L., Graneto D., Medendorp S. V. Alternative immunosuppressive strategies in the management of recipients of living related renal transplants. Transplant Proc. 1989 Feb;21(1 Pt 2):1609–1614. [PubMed] [Google Scholar]
  9. Kostakis A., Homatas J., Kyriakidis S., Garbis S., Zavos G., Sotirchos G., Diles K., Bokos J., Stathakis C., Boletis J. Experience with triple immunosuppressive therapy in living related donor kidney transplantation. Transplant Proc. 1991 Aug;23(4):2223–2223. [PubMed] [Google Scholar]
  10. Linder R., Restifo A. C., Lindholm A., Groth C. G. Long-term cyclosporine A treatment does not progressively impair renal graft function: a 5-year follow-up study. Transplant Proc. 1991 Aug;23(4):2210–2210. [PubMed] [Google Scholar]
  11. Ota K., Takahashi K., Toma H. Cyclosporine-treated kidney transplants from living-related donors--a single center trial. Clin Transpl. 1988:189–198. [PubMed] [Google Scholar]
  12. Perez R. V., Matas A. J., Gillingham K. J., Payne W. D., Canafax D. M., Dunn D. L., Gores P. F., Sutherland D. E., Najarian J. S. Lessons learned and future hopes: three thousand renal transplants at the University of Minnesota. Clin Transpl. 1990:217–231. [PubMed] [Google Scholar]
  13. Sollinger H. W., Deierhoi M., Kalayoglu M., Belzer F. O. Sequential antilymphocyte globulin cyclosporine therapy in cadaver renal transplantation. Transplant Proc. 1986 Apr;18(2 Suppl 1):16–18. [PubMed] [Google Scholar]

Articles from Annals of Surgery are provided here courtesy of Lippincott, Williams, and Wilkins

RESOURCES